Cargando…
AI-driven drug discovery: A boon against COVID-19?
The COVID-19 is an issue of international concern and threat to public health and there is an urgent need of drug/vaccine design. There is no vaccine or specific drug yet made as of July 23, 2020, for the coronavirus disease (COVID-19). Thus, the patients currently can only be treated symptomaticall...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396325/ http://dx.doi.org/10.1016/j.aiopen.2020.07.001 |
_version_ | 1783565558175760384 |
---|---|
author | Chandra Kaushik, Aman Raj, Utkarsh |
author_facet | Chandra Kaushik, Aman Raj, Utkarsh |
author_sort | Chandra Kaushik, Aman |
collection | PubMed |
description | The COVID-19 is an issue of international concern and threat to public health and there is an urgent need of drug/vaccine design. There is no vaccine or specific drug yet made as of July 23, 2020, for the coronavirus disease (COVID-19). Thus, the patients currently can only be treated symptomatically. A quick identification of the drugs for COVID-19 may act as a potential therapeutic medication which has been used earlier in patients to answer the present pandemic condition before it could get more worse. According to our view, an artificial intelligence (AI) based tool that may predict drugs/peptides directly from the sequences of infected patients and thereby, they might have better affinity with the target and contribute towards vaccine design against COVID-19. Researchers across the world proposed several vaccines/drugs for COVID-19 utilizing AI based approaches, however, testing of these proposed vaccines/drugs will be needed to verify the safety and feasibility for combating COVID-19. |
format | Online Article Text |
id | pubmed-7396325 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The Authors. Published by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73963252020-08-03 AI-driven drug discovery: A boon against COVID-19? Chandra Kaushik, Aman Raj, Utkarsh AI Open Article The COVID-19 is an issue of international concern and threat to public health and there is an urgent need of drug/vaccine design. There is no vaccine or specific drug yet made as of July 23, 2020, for the coronavirus disease (COVID-19). Thus, the patients currently can only be treated symptomatically. A quick identification of the drugs for COVID-19 may act as a potential therapeutic medication which has been used earlier in patients to answer the present pandemic condition before it could get more worse. According to our view, an artificial intelligence (AI) based tool that may predict drugs/peptides directly from the sequences of infected patients and thereby, they might have better affinity with the target and contribute towards vaccine design against COVID-19. Researchers across the world proposed several vaccines/drugs for COVID-19 utilizing AI based approaches, however, testing of these proposed vaccines/drugs will be needed to verify the safety and feasibility for combating COVID-19. The Authors. Published by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. 2020 2020-08-03 /pmc/articles/PMC7396325/ http://dx.doi.org/10.1016/j.aiopen.2020.07.001 Text en © 2020 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Chandra Kaushik, Aman Raj, Utkarsh AI-driven drug discovery: A boon against COVID-19? |
title | AI-driven drug discovery: A boon against COVID-19? |
title_full | AI-driven drug discovery: A boon against COVID-19? |
title_fullStr | AI-driven drug discovery: A boon against COVID-19? |
title_full_unstemmed | AI-driven drug discovery: A boon against COVID-19? |
title_short | AI-driven drug discovery: A boon against COVID-19? |
title_sort | ai-driven drug discovery: a boon against covid-19? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396325/ http://dx.doi.org/10.1016/j.aiopen.2020.07.001 |
work_keys_str_mv | AT chandrakaushikaman aidrivendrugdiscoveryaboonagainstcovid19 AT rajutkarsh aidrivendrugdiscoveryaboonagainstcovid19 |